Navigation Links
Also in the June 10 JNCI

Novel Targeted Therapy Reduces Chemoresistance in Mouse Model of Melanoma

A novel small molecule inhibitor reduced both endogenous and drug-induced resistance to chemotherapy in a mouse model of melanoma.

The NF-κB pathway is often active in human cancers and promotes resistance to cytotoxic chemotherapy drugs. Some cytostatic drugs, such as doxorubicin, induce NF-κB pathway activity.

To determine if a new inhibitor of the pathway, called KINK-1, could overcome this resistance, Michael Schn, M.D., of the University Medical Center Gttingen in Germany and colleagues injected mice with melanoma cells and then treated them with doxorubicin and KINK-1.

They found that mice treated with a combination of the two drugs developed smaller lung metastases than mice treated with either agent alone.

"Based on our observation that the compound suppressed constitutive NF-κB activation and NF-κB activation induced by cytostatics or inflammatory agents, KINK-1 appears to be a universal inhibitor of NF-κB activation in melanoma cells, regardless of the mode of activation," the authors write.

In an accompanying editorial, John Kirkwood, M.D., of the University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute and colleagues review the biology of NF-κB and its impact on melanoma cells. Other inhibitors of the pathway have been tried in melanoma and did not prove successful. The KINK-1 inhibitor blocks the pathway in a different manner and may have a bigger impact on the disease, though that must be tested in a clinical trail. "These new agents may be most beneficially combined with chemotherapeutic agents to which melanoma has been refractory in the past," the editorialists conclude.


Low Melatonin Associated with Increased Risk of Breast Cancer in Postmenopausal Women

Low melatonin levels are associated with an increased risk of breast cancer in postmenopausal women, according to a prospective case-control study.

Melatonin is primarily secreted during the dark hours of a light-dark cycle and has been shown to be low in some night workers. Researchers have found that low melatonin levels in premenopausal women are associated with an increased risk of breast cancer.

To find out if a similar association occurs in postmenopausal women, Eva Schernhammer, M.D., Dr.P.H., of the Brigham and Women's Hospital and Harvard Medical School in Boston and colleagues compared melatonin levels in 178 postmenopausal women and 710 matched controls. All of the women were enrolled in the prospective Hormones and Diet in the Etiology of Breast Cancer Risk study.

The researchers found that women with the lowest levels of melatonin had a statistically significantly higher incidence of breast cancer than those with the highest levels.

The researchers conclude that low melatonin levels are associated with an increased risk of breast cancer. Further studies need to confirm these data and should investigate the mechanisms that underlie the association.

Contact: Lori Shanks,, (617) 534-1604


Contact: Liz Savage
Journal of the National Cancer Institute

Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... ... unique analog distortion effect tool designed specially for Final Cut Pro X. ... limiltess looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is ...
(Date:11/28/2015)... ... , ... Trying to relax on a couch can actually be uncomfortable, so ... design due to personal experience with a bad back," he said. , This easy-to-use, ... well as increases support. It also makes it easier to eat, do other activities ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: